Compounds > carbostyril
Page last updated: 2024-08-17

carbostyril and Local Neoplasm Recurrence

carbostyril has been researched along with Local Neoplasm Recurrence in 16 studies

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (31.25)29.6817
2010's7 (43.75)24.3611
2020's4 (25.00)2.80

Authors

AuthorsStudies
Appelbaum, FR; Cooper, BW; Craig, MD; Kaminer, LS; Karp, J; Ketterling, RP; Larson, RA; Lazarus, H; Litzow, MR; Luger, SM; Makary, AZ; Paietta, E; Rowe, JM; Rybka, WB; Tallman, MS; Wang, VX1
Aggarwal, R; Brose, M; Chau, NG; Cohen, EEW; Gualberto, A; Guenette, JP; Hanna, GJ; Ho, AL; Metcalf, R; Pérez-Ruiz, E; Razaq, M; Sayehli, CM; Scholz, C; Wilhelm, C; Wong, DJ1
Alhawas, L; Amin, KS; Banerjee, PP; Salla, B1
Burggraaf, J; Burgmans, MC; Coenraad, MJ; Fariña Sarasqueta, A; Osanto, S; van Wezel, JT; Wasser, MNJM; Weijl, NI; Woei-A-Jin, FJSH1
Dillon, PM; Douvas, MG; Fracasso, PM; Horton, BJ; Moskaluk, CA; Petroni, GR; Thomas, CY; Varhegyi, N; Zaja-Milatovic, S1
Abrey, LE; Aldape, K; Chang, S; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Ebiana, VA; Gilbert, M; Kuhn, J; Levin, VA; Lieberman, F; Mehta, MP; Nghiemphu, PL; Prados, M; Robins, HI; Wen, P; Wright, JJ; Yung, WKA1
Day, AG; Elliott, BE; Ghaffari, A; Greer, PA; Hoskin, V; Kiefer, F; Madarnas, Y; Mewburn, J; Mullins, G; SenGupta, S; Turashvili, G; Varma, S1
Ahluwalia, MS; Elson, P; Hobbs, BP; McCrae, K; Nixon, AB; Peereboom, DM; Schilero, C; Sharma, M; Stevens, GHJ1
Berry, I; Catalaa, I; Celsis, P; Cohen-Jonathan Moyal, E; Deviers, A; Filleron, T; Ken, S; Laprie, A; Laruelo, A; Lubrano, V; Mogicato, G; Rowland, B1
Bouabdallah, R; Briere, J; Chassagne-Clement, C; De Kerviler, E; Franchi, P; Ghesquieres, H; Haioun, C; Houlgatte, R; Jais, JP; Jardin, F; Raponi, M; Ribrag, V; Rolland, D; Thieblemont, C1
Adamson, PC; Arceci, RJ; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Goodwin, A; Jayaprakash, N; Widemann, BC; Wright, JJ; Zannikos, P1
Berk, S; Gajewski, TF; Harlin, H; Karrison, T; Larson, RA; Odenike, OM; Ratain, MJ; Sprague, E; Stock, W; Zimmerman, TM1
Abrey, L; Chang, S; Cloughesy, TF; DeAngelis, L; Fink, K; Groves, M; Junck, L; Kuhn, J; Lamborn, K; Lieberman, FS; Mehta, M; Paquette, S; Prados, M; Robins, HI; Schiff, D; Sebti, SM; Wen, P; Wright, J; Yung, A1
Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; DeAngelis, LM; Fink, KL; Gilbert, MR; Groves, MD; Junck, L; Kuhn, J; Lamborn, KR; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Schiff, D; Wen, PY; Wright, J; Yung, WK1
Atkins, D; Harousseau, JL; Lancet, JE; Löwenberg, B; Rackoff, W; Raponi, M; Stone, R; Wang, Y; Zhang, Y1

Trials

14 trial(s) available for carbostyril and Local Neoplasm Recurrence

ArticleYear
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
    Leukemia research, 2021, Volume: 111

    Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quinolones; Salvage Therapy; Survival Rate

2021
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
    Cancer, 2020, 09-01, Volume: 126, Issue:17

    Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Quinolones; Salivary Gland Neoplasms; Treatment Outcome

2020
Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study.
    The oncologist, 2021, Volume: 26, Issue:10

    Topics: Angiogenesis Inhibitors; Benzimidazoles; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Placenta Growth Factor; Quinolones; Vascular Endothelial Growth Factor A

2021
A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-01, Volume: 23, Issue:15

    Topics: Adult; Aged; Benzimidazoles; Carcinoma, Adenoid Cystic; Cell Proliferation; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oncogene Proteins v-myb; Quinolones; Receptor, Fibroblast Growth Factor, Type 1

2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
    Journal of neuro-oncology, 2018, Volume: 136, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Sorafenib; Treatment Outcome

2018
Phase II study of Dovitinib in recurrent glioblastoma.
    Journal of neuro-oncology, 2019, Volume: 144, Issue:2

    Topics: Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quinolones; Survival Rate

2019
Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
    International journal of radiation oncology, biology, physics, 2014, Oct-01, Volume: 90, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Choline; Creatine; Female; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Radiotherapy, Conformal; Sensitivity and Specificity

2014
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4

    Topics: A Kinase Anchor Proteins; Administration, Oral; Aged; Antineoplastic Agents; DNA-Binding Proteins; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lymphoma, Mantle-Cell; Male; Minor Histocompatibility Antigens; Neoplasm Recurrence, Local; Nuclear Proteins; Predictive Value of Tests; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Treatment Outcome

2010
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
    Pediatric blood & cancer, 2011, Volume: 56, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Farnesyltranstransferase; Female; Half-Life; Humans; Infant; Leukemia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Quinolones

2011
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Dec-01, Volume: 22, Issue:23

    Topics: Administration, Oral; Aged; Aged, 80 and over; Analysis of Variance; Biological Availability; Blotting, Western; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Risk Assessment; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Treatment Outcome

2004
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-20, Volume: 23, Issue:27

    Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinolones; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome

2005
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-01, Volume: 24, Issue:22

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Induction; Epilepsy; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Quinolones; Treatment Outcome

2006
E2902: A Phase III randomized study of farnesyl transferase inhibitor R115777 in acute myeloid leukemia patients in second or subsequent remission or in remission after primary induction failure or patients over age 60 in first remission.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:1

    Topics: Aged; Antineoplastic Agents; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Salvage Therapy

2007
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-01, Volume: 13, Issue:7

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Predictive Value of Tests; Quinolones; Reverse Transcriptase Polymerase Chain Reaction

2007

Other Studies

2 other study(ies) available for carbostyril and Local Neoplasm Recurrence

ArticleYear
T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
    Carcinogenesis, 2021, 04-17, Volume: 42, Issue:3

    Topics: Alternative Splicing; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Male; Mitogen-Activated Protein Kinase Kinases; Neoplasm Recurrence, Local; Prognosis; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinolones; Receptors, Androgen; Signal Transduction; Thiophenes; Transcriptional Activation

2021
Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.
    Breast cancer research : BCR, 2019, 01-24, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cohort Studies; Cytoskeletal Proteins; Disease Models, Animal; Female; Genes, Reporter; Humans; Intravital Microscopy; Lung; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Neoplasm Recurrence, Local; Phenols; Quinolones; Tissue Array Analysis

2019